DexCom CEO Kevin Sayer takes temporary medical leave; Jacob Leach appointed interim CEO

DEXCOM INC

Kevin R. Sayer, CEO and Chairman, takes temporary medical leave effective Sept 14, 2025.
Jacob S. Leach, President and COO, appointed interim principal executive officer.
Mark Foletta, Lead Independent Director, appointed interim chairman of the Board.
No additional compensation for interim appointments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.